🇺🇸 FDA
Pipeline program

TAK-583

01-06-TL-583-006

Phase 2 small_molecule completed

Quick answer

TAK-583 for Diabetic Neuropathies is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Diabetic Neuropathies
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials